Background. Phylogenetic comparisons of known Marburg virus (MARV) strains reveal 2 distinct genetic lineages: Ravn and the Lake Victoria Marburg complex (eg, Musoke, Popp, and Angola strains). Nucleotide variances of >20% between Ravn and other MARV genomes suggest that differing virulence between lineages may accompany this genetic divergence. To date, there exists limited systematic experimental evidence of pathogenic differences between MARV strains.
Since the discovery of Marburg virus (MARV) during the original outbreak in 1967, it has caused sporadic outbreaks of severe hemorrhagic fever in Central Africa, with case-fatality rates (CFRs) ranging from 23% to 90% [1] [2] [3] . Research has focused on a handful of strains obtained from these outbreaks, with an emphasis on the Musoke, Ravn (MARV-Rav), and Angola (MARVAng) strains. The Musoke strain was first isolated in 1980 from a physician who survived nosoco-mial transmission from a patient infected in Nzoia, Kenya [4] . MARV-Rav was first isolated in 1987 from a case originating in southeastern Kenya but has been associated with large outbreaks of Marburg hemorrhagic fever (MHF) in the Democratic Republic of the Congo during 1998-2000, where strain-specific CFR metrics were impossible to enumerate because of concurrent circulation of multiple strains [1, 3] . MARV-Ang was responsible for the largest documented outbreak (252 cases) of MHF, in which a 90% CFR was reported, a rate very similar to that of the most virulent strains of Ebola virus [2] .
Phylogenetic comparisons across MARV strains reveal 2 distinct genetic lineages: Ravn and the Lake Victoria Marburg complex (eg, Musoke, Ci67, Popp, and Angola strains), wherein nucleotide variances of >20% between Ravn and other MARV genomes exist [2] . The level of genetic divergence and variation in CFR between strains suggest that these changes may contribute to variation in virulence. Many studies to characterize the pathogenesis of MARV infection have occurred since the original outbreak; however, some variability exists between these reports, depending on which strain of MARV was used [5] [6] [7] [8] . This presents challenges for medical countermeasure development, such that inherent genetic differences may contribute to altered disease outcome across MARV strains, and thus any countermeasure or diagnostic assay may need evaluation across MARV strains.
Until recently, most MARV-specific countermeasures were tested in vivo, using mice or inbred strain 13 guinea pigs (GPs) [9] [10] [11] . Limitations in interpretation are necessary because delayed immunoresponsiveness and incomplete recapitulation of hallmark features of MHF (fever, diarrhea, weight loss, coagulopathies, vascular leak, and marked immune derangement similar to sepsis) may factor into the limited predictive value that these models have had to date [12] . Recently, we developed uniformly lethal outbred GP models for several strains of MARV by serial adaptation. These GP-adapted (GPA) MARV strains have demonstrated predictive efficacy in postexposure treatment in nonhuman primates (NHPs) [5, 13] . Here, we performed a temporal comparison of the events leading to death in outbred GPs infected with GPA MARV-Ang and MARV-Rav. We report not only remarkable similarities between MHF in NHPs and MHF in humans but also MARV strain-specific differences in virulence.
MATERIALS AND METHODS

Virus Adaptation
MARV-Ang and MARV-Rav strains were adapted to uniform lethality in outbred Hartley strain GPs by serial passage of virus isolated from infected livers and/or spleens and sequenced as outlined in the Supplementary Methods [14] .
Inoculation of GPs
Animal studies were conducted under biosafety level 4 (BSL4) containment at the Galveston National Laboratory and were approved by the University of Texas Medical Branch (UTMB) Institutional Laboratory Animal Care and Use Committee. Female outbred Hartley strain GPs (weight, approximately 351-400 g) from Charles River Laboratories were quarantined upon receipt and acclimatized for approximately 1 week prior to MARV challenge. Forty animals were divided into 11 groups of 4 animals per group, with 5 groups per virus strain and 1 uninfected control group. Individual animals were challenged with approximately 5000 plaque-forming units (PFU) of GPA MARV-Ang or GPA MARV-Rav or mock challenged with Hanks' balanced salt solution with 2% fetal bovine serum, by intraperitoneal injection.
Necropsy
Each group of MARV-infected GPs was euthanized on postinfection days 1, 3, 5, or 7 or at a terminal point, when euthanasia criteria was met (n = 4/group/day). Clinical signs, weights, and transponder-mediated temperatures were recorded daily up to the time of euthanasia. Prior to necropsy, whole-blood, plasma (in ethylenediaminetetraacetic acid-lined tubes), and citrated plasma specimens were collected by cardiac puncture for hematologic analysis, serum/plasma biochemical assays, and viremia determination. Gross findings were documented, and select tissue specimens were aseptically removed and frozen at −70°C until analysis. The following tissue specimens were collected from all animals for histologic and immunohistochemistry analyses: liver, spleen, kidney, adrenal gland, lung, brain, lymph nodes (axillary, inguinal, mesenteric, and mandibular), salivary gland, trachea, esophagus, stomach, duodenum, ileocecal junction, colon, urinary bladder, reproductive tract, pancreas, haired skin, and heart.
Histologic and Immunohistochemistry Analyses
Selected tissues were fixed in formalin for at least 21 days in a BSL-4 facility. Specimens were then removed from the BSL-4 facility and processed in a BSL-2 facility, using routine histopathologic procedures, as outlined in the Supplementary Materials.
Hematologic Analysis, Serum Biochemistry Analysis, and Determination of Coagulation Parameters
Complete blood counts, analysis of coagulation dynamics, and analysis of blood chemistry parameters were performed on blood, serum, or plasma specimens. Analysis of select cytokines, coagulation factors, eicanosoids, and nitric oxide in serum or plasma specimens was also performed as detailed in the Supplementary Materials.
Virus Isolation
Determination of infectious virus in plasma, spleen, liver, kidney, adrenal, pancreas, lung, and brain tissue homogenates was made using standard plaque assays, as outlined in the Supplementary Materials.
Statistics Statement
Conducting animal studies in a BSL-4 facility severely restricts the number of animal subjects, the volume of biological samples that can be obtained, and the ability to repeat assays independently, thus limiting the power of statistical analysis. Consequently, data are presented as the mean values calculated from replicate samples, not replicate assays, and error bars represent standard deviations across replicates.
RESULTS
Adapted Virus Sequence Analysis
Sequence comparison of GPA MARV-Ang with the prototype strain (accession number DQ447653.1) revealed nucleotide substitutions resulting in a single amino acid change in VP40 and 2 changes in VP24, both viral matrix proteins. Three nucleotide changes were discovered in noncoding regions, and 2 silent mutations were detected in the polymerase gene. Comparison of GPA MARV-Rav with prototype MARV-Rav (accession number DQ447649.1) revealed nucleotide substitutions resulting in a single amino acid change in both NP and glycoprotein and 4 changes in VP40. One silent mutation in the polymerase gene was also detected. The resulting mutations may have been acquired during the consecutive passages in GPs and/ or passages in Vero 76 cells during seed stock production ( Table 1) .
Virus Titers in Blood and Tissues
Plasma viremia was first detected on day 3 for both MARV-Ang and MARV-Rav strains, with equivalent titers of approximately 2.7 log 10 PFU/mL. The peak MARV-Ang viremia level of approximately 7. 9 log 10 PFU/mL on day 7 was maintained through terminal collections. The MARV-Rav viremia level peaked at approximately 6.4 log 10 PFU/mL at terminal collection. Virus was recovered from spleen, pancreas, lung, kidney, liver, adrenal gland, and plasma from both MARV-Ang and MARV-Rav groups beginning on day 3, with higher titers detected in spleen, lung, and liver homogenates from the MARV-Ang group. On day 7, higher mean titers were recorded in liver and plasma from Marv-Ang-infected animals, whereas higher mean titers were observed in spleen, lung, kidney, and adrenal glands from MARV-Rav-infected animals. The highest titers in lung, kidney, adrenal gland, and plasma were measured at terminal collection in MARV-Ang-infected animals ( Table 2) .
Gross Findings
GPs from terminal groups were followed for mean changes in weights, temperature, and time to death. MARV-Ang-infected animals from this group met euthanasia criteria a mean of 1 day earlier than subjects from the MARV-Rav group ( Figure 1A) . Mean body weights at the time of necropsy were compared with initial weights, with comparable progressive weight loss between virus strain cohorts noted. Mean percentages changes in weights for MARV-Rav-infected GPs were −1.8% on day 5, −8.4% on day 7, and −25% at the terminal time point. MARV-Ang-infected animals began losing weight on day 6 (mean percentage change, −1.3%), with mean percentages changes of −6% on day 7 and −12.5% at terminal time points. MARV-Rav-infected animals had higher mean temperatures beginning on day 3 and remained at +1°C until day 7, when a peak of +1.5°C was followed by progressive hypothermia until time of death. MARV-Ang-infected animals had slowly progressive fevers that peaked at +1°C on day 6 and were also followed by hypothermia. Mock-infected control animals maintained stable weight and core temperature during the study ( Figure 1B) .
No gross lesions were present in the mock-infected control GPs ( Figure 1C ). Gross lesions present at necropsy of both MARV-Rav-infected GPs and MARV-Ang-infected GPs appeared on day 3 and increased in severity over the course of the study. The most significant gross lesions included splenic mottling with enlargement, multifocal to diffuse hepatic pallor, lymphadenomegaly, and gastrointestinal congestion with ulceration ( Figure 1D-F ) . The severity of gastrointestinal and hepatic lesions in the terminal MARV-Ang-infected GPs ( Figure 1D and 1F) were more prominent than those in the terminal MARV-Rav-infected GPs ( Figure 1E ). Detailed gross findings are available in the Supplementary Materials.
Hematologic Findings
Total and differential white blood cell counts for both strains of MARV elicited marked evidence of neutrophilia-mediated leukocytosis. Strikingly elevated circulating levels of neutrophils were noted beginning on 3 day and peaked on day 5 after infection for both strains. A concurrent marked lymphopenia was observed, as evidenced by declining mean lymphocyte counts. Thrombocytopenia, compared with control values, was marked, beginning at day 5 and continuing through terminal collection. Increases in mean platelet volume were also noted, beginning on day 5 and continuing through death for both infected groups. Basophilia and eosinophilia began on day 5 and progressed through death (Table 3) .
Serum Biochemistry Findings
No remarkable changes were noted in early serum enzyme levels but most were elevated in late disease. Beginning day 7 and continuing to death, remarkable 10-fold increases in circulating levels of aspartate transaminase and alkaline phosphatase were present in both MARV strains. More-modest increases in levels of alanine transaminase (approximately 2.5-fold) and gammaglutamyl transpeptidase (approximately 6-fold) were detected at late-stage disease. The total bilirubin level was within normal limits until day 7, after which it doubled in MARV-Rav-infected animals and tripled in MARV-Ang-infected animals at termination time points. Blood urea nitrogen levels remained consistent throughout infection in MARV-Ang-infected animals; however, a 2-fold increase was observed at final time points in MARV-Rav-infected animals. Hypoalbuminemia with concurrent hypoproteinemia began on day 5 (Table 3) .
Histopathologic and Immunohistochemistry Findings
Histopathologic lesions and immunoreactivity for MARV antigen in tissues of MARV-infected GPs were most apparent by day 3, with the severity of the lesions increasing over the duration of the study. MARV antigen associated with histologic lesion severity was similar between both MARV-Rav-infected animals and MARV-Ang-infected animals; however, infection by cell type was different, with obvious progression of up to 2 days sooner in the MARV-Ang group, compared with the MARV-Rav group. No significant histopathologic lesions, presence of viral antigen, or abnormal fibrin was observed in mockinfected control GP tissues.
Liver
Beginning on day 3, MARV antigen-positive Kupffer cells were observed for both MARV-Rav-infected GPs (3 of 4; Figure 2B ) and MARV-Ang-infected GPs (4 of 4; Figure 2D ). Additionally, minimal individualized hepatocytes (MARV-Rav-infected GPs) and small clusters of adjacent hepatocytes (MARVAng-infected GPs) had immunoreactivity. Lesions on hematoxylin and eosin (H/E)-stained sections associated with MARV antigen were detected on day 3, with hepatocellular degeneration/necrosis and sinusoidal leukocytosis in 3 of 4 MARV-Rav-infected GPs and 4 of 4 MARV-Ang-infected GPs. The prevalence of MARV antigen-positive Kupffer cells and clusters of hepatocytes increased throughout the study for Comparative 
Spleen
On day 3, MARV antigen-positive mononuclear/dendritiform cells were observed for both MARV-Rav-infected GPs (3 of 4) and MARV-Ang-infected GPs (4 of 4; Figure 3B and 3E). Key differences on day 3 were immunoreactive cells scattered throughout the red pulp only for MARV-Rav-infected GPs and small clusters of immunoreactive cells within the red and white pulp for MARV-Ang-infected GPs. Corresponding congestion and tingible body macrophages were noted on H/Estained sections of spleens from both MARV-Rav-infected GPs and MARV-Ang-infected GPs. Immunoreactive cells within the spleen peaked at day 3 for MARV-Ang-infected GPs ( Figure 3E ) and by day 5 for MARV-Rav-infected GPs ( Figure 3H ), with dispersion of MARV antigen-positive cells throughout the spleen by the end of the study. All animals, beginning on day 3 and continuing to death, had progressive lymphocyte depletion with tingible body macrophages, hemorrhage, and fibrin deposition within the white pulp. TUNEL staining of apoptotic populations within the splenic germinal centers increased over time, with peak intensity on day 5 for MARV-Ang-infected GPs ( Figure 3L ) and in terminal specimens for MARV-Rav-infected GPs ( Figure 3U ). Fibrin was scattered throughout the red pulp and clustered within the white pulp in MARV-Rav-infected GPs ( Figure 4B ). Fibrin immunolabeling of strands and aggregates within vessels, along the endothelium, and in clusters that disperse into the adjacent red and white pulp were present in MARV-Ang-infected GPs ( Figure 4C and 4D ).
Lymphoid Tissues
Beginning on day 5 and increasing in severity to the end of the study, lymphoid depletion was observed in mandibular (10 of 12 MARV-Rav-infected GPs and 11 of 12 MARV-Ang-infected GPs), axillary (8 of 12 and 8 of 12, respectively), and inguinal (8 of 12 and 8 of 12, respectively) lymph nodes. MARV antigen was noted in scattered mononuclear cells within the subcapsular and medullary sinuses of lymph nodes for both MARV-Rav and MARV-Ang groups. TUNEL staining of apoptotic populations within the mandibular lymph nodes increased over time, with peak intensity on day 5 for MARV-Ang-infected GPs and day 7 for MARV-Rav-infected GPs.
Adrenal Gland MARV antigen-positive interstitial cells of the adrenal medulla were present in 4 of 4 MARV-Ang-infected GPs on day 3 and 4 of 4 MARV-Rav-infected GPs on day 5, yet no significant lesions were observed on H/E-stained sections. Subsequently, infection progressively extended into the interstitial cells of the cortex and cortical cells until death for both the MARV-Rav group (12 of 12 GPs) and the MARV-Ang group (12 of 12 GPs). Beginning on day 7, hemorrhage at the corticomedullary junction corresponded with immunoreactivity for both MARV-Rav-infected GPs (7 of 8) and MARV-Ang-infected GPs (7 of 8).
Lung MARV antigen-positive alveolar macrophages and mononuclear cells within alveolar septae were observed on day 7 and at terminal time points for both MARV-Rav-infected GPs (7 of 8) and MARV-Ang-infected GPs (8 of 8), which corresponded with interstitial pneumonia (Supplementary Figure 2B and 2C ).
Urogenital Tract
Beginning on day 7, MARV antigen was observed in submucosal interstitial cells and the transitional epithelium of the urinary bladder in MARV-Rav-infected GPs (3 of 8) and MARV-Ang-infected GPs (4 of 8; Supplemental Figure 1E and 1F ). Lymphohistiocytic vasculitis of the urinary bladder submucosa was present in terminal specimens from MARVRav-infected animals, yet no lesions were noted in MARVAng-infected GPs. MARV antigen-positive mononuclear interstitial cells within the uterus, often surrounding small vessels and follicular thecal cells, were present at terminal time points of both MARV-Rav-infected GPs (2 of 2) and MARVAng-infected GPs (2 of 2), yet no significant lesions were observed on H/E-stained sections (data not shown). 
Gastrointestinal Tract
A focal gastric ulceration was noted in a terminal specimen from 1 MARV-Ang GP. Beginning on day 7, with progression to death, lymphoid depletion in MARV-Rav GPs was noted in the thymus (7 of 8 animals), ileocecal junction (8 of 8), and duodenum (8 of 8); similar findings were also observed in MARVAng-infected GPs (8 of 8, 8 of 8, and 6 of 8, respectively). TUNEL staining of apoptotic populations within the lamina propria of the duodenum at death of a MARV-Ang-infected GP was most striking, extending from the villar tips to the submucosa, compared with that of a MARV-Rav-infected GP, which extended approximately one fourth of the way down the villar tip (Supplementary Figure 2G-I ).
Coagulation Parameters
Prothrombin times began to extend significantly beginning at day 3 and continued to lengthen throughout the course of disease. Activated partial thromboplastin times (APTTs) were not extended until late in disease, beginning on day 7. Beginning on day 1, decreases in thrombin times corresponded with increases in fibrinogen content throughout the disease course. Circulating protein C activity and tissue factor levels progressively decreased; Figure 4 . Fibrin specific immunohistochemistry of GP spleens: Control GP had no significant immunolabeling (A). Day 7 MARV-Rav-infected GP had minimal anti-fibrin immunolabeling scattered throughout the red pulp and clustered in the white pulp (B). Day 7 MARV-Ang-infected GP with anti-fibrin immunolabeling scattered throughout the red pulp and clustered in the white pulp (C). Inset depicts representative immunolabeling of fibrin strands and aggregates surrounding red and white blood cells within the vessel, along the endothelium, and clusters that disperse into the adjacent red and white pulp (D). All 20× with 60× insert in (D). Heat map and expression levels of coagulation factors and inflammatory molecules detected through the course of infection (E). Abbreviations: APTT, activated partial thromboplastin times; GP, guinea pig; HMGB-1, high-mobility group B1; IL-6, interleukin 6; MARV, Marburg virus; NO, nitric oxide; PAI-1, plasminogen activator inhibitor 1; PT, partial thrombin; SD, standard deviation; TAFI, thrombin-activated fibrinolysis inhibitor; TGF, transforming growth factor; TNF, tumor necrosis factor; TT, thrombin time; VWF, Von Willebrand factor.
however, plasminogen activator inhibitor 1 (PAI-1) and von Willebrand factor levels were markedly increased in late disease. The mean thrombin-activated fibrinolysis inhibitor (TAFI) level began to increase markedly on day 3 in MARV-Rav-infected GPs and stayed elevated through death. Conversely, MARVAng-infected GPs did not have an increased mean level of TAFI until late in disease. Interestingly, circulating tissue factor levels decreased gradually until the time of death. Bradykinin levels gradually increased to approximately 6-fold higher than those in control animals at late points in disease. Conversely, prekallikrein levels were severely depressed until late in the disease course, when, at day 7, a striking increase was recorded in MARV-Ang-infected GPs but not in MARV-Rav-infected animals. Circulating levels of thrombin in complex with thrombomodulin were noted beginning on day 1 and increased throughout the disease course for both strains ( Figure 4E ).
Circulating Eicanosoid, Cytokine, and Nitric Oxide Production
Mean levels of prostaglandin E2 began to decrease on day 1, with a continued decrease to day 3. Beginning on day 5, however, marked increases were noted in mean values, with the terminal mean value approximately 3 times that of control animals. The mean leukotriene B4 value was elevated in MARVAng animals on day 1 and tended to increase over the disease course to approximately 4 times the level in control animals. MARV-Rav-infected animals demonstrated a similar trend, beginning on day 3, but with comparatively muted mean levels. Mean cysteinal leukotriene levels gradually increased throughout the course of infection, beginning on day 5. Thromboxane B2 levels were elevated in MARV-Rav-infected animals beginning on day 3 and continuing through terminal time points; conversely, MARV-Ang-infected animals did not have significant difference in levels of this eicansoid. Prostacyclin levels were measured via the stable metabolite 6-keto-prostaglandin F1a and were first elevated in MARV-Rav-infected animals beginning on day 3; MARV-Ang-infected animals demonstrated a marked increase on day 5. Transforming growth factor β, interleukin 6, and tumor necrosis factor α values were marked late in disease through death. Very soon after infection, mean levels of HMGB-1 were higher in MARV-Rav-infected GPs, compared with MARVAng-infected GPs, yet both were markedly elevated as compared to those in control animals throughout the study. Circulating nitrite levels were increased in both species, beginning on day 5; however, striking increases were recorded in MARV-Anginfected animals in late disease ( Figure 4E ).
DISCUSSION
The increased frequency and severity of filovirus outbreaks in recent years underscores the dire need for medical countermeasures. The development of rodent models that faithfully represent MHF processes yet maintain predictive power for filovirus-specific countermeasures could facilitate scale up of screening efforts of these medical interventions and thereby restrict precious primate resources to only the most likely candidate countermeasures. Inbred rodent models are commonly used to model a variety of disease processes but have limitations in regard to their well-documented depressed immune capacity. This caveat is a major shortcoming for vaccines and therapeutic development, which maintain heavy reliance on various aspects of host immunity for efficacy. To further complicate the issue, limited descriptions of coagulopathies or vascular leak in rodent models of MHF exist, thereby limiting the power of these models.
To address the need for improved rodent models, we presented 2 outbred GP models that demonstrate not only hallmark features of MHF, but also provide systematic evidence for differences in pathogenicity among phylogenetically diverse MARV strains. Both models recapitulate important aspects of NHP and human MHF pathogenic features, including fever, weight loss, and early infection of macrophage/dendritiform cells, followed by remarkable splenic and hepatic pathology, lymphocyte apoptosis, neutrophilia, thrombocytopenia, and marked granulocytosis. Perturbations in serum biochemistry findings in NHP and human MHF were also similar, specifically in regard to marked increases in liver-associated enzyme levels, proinflammatory cytokine levels, nitric oxide species and hypoalbuminemia. This work also details a severe coagulopathy, which includes increased prothrombin and APTTs, decreased thrombin times, decreased protein C activity, marked fibrinogen deregulation, increased prostacyclin, thromboxane, von Willebrand factor, PAI-1, and circulating thrombin-thrombomodulin complex levels, and deposition of fibrin in tissues, all of which have been demonstrated in MHF in NHPs and humans [15] [16] [17] [18] [19] . Although decreased serum tissue factor was also documented, we have yet to clarify whether levels are elevated in tissues, as previously documented in NHPs [20] .
Given the similarities in pathogenesis between viral hemorrhagic fever and sepsis [21, 22] , we probed this model for several pathologically relevant phenomena that are important in bacterial sepsis. We detected evidence for activation of the kallikrein-kinin system and disruption of fibrinolysis processes, as evidenced by abrogated bradykinin, prekallikrein, and TAFI metabolism. Deregulation of circulating eicanosoids has also been associated with sepsis [23, 24] . Accordingly, we documented deregulation of several important species of prostaglandins and leukotrienes late in disease. Recent work in sepsis has also suggested the importance of proinflammatory cytokine/ transcription factor HMGB-1 in disease severity [25, 26] . Our data suggest a role for this molecule in early MHF that may lend to differences in pathogenesis between MARV strains.
Prior work with the Musoke strain of MARV identified several mutations necessary for lethality in strain 13 GPs; however, sequencing of the GPA MARVs from this work revealed multiple changes, of which none had been previously described [27] .
Both MARV strains adopted genetic mutations that resulted in amino acid changes within the VP40 proteins; however, only MARV-Ang had changes in VP24, a protein recognized to be important in formation of infectious particles and interaction with cytoprotective antioxidant response pathways [28, 29] . Given the higher viral burden in tissues and plasma, marked increases in severe inflammation, and shorter mean time to death, this finding suggests that VP24 is a potential molecular landmark responsible for virulence differences between MARV species. The recently developed reverse genetics system for MARV will allow for a more mechanistic approach to identify which mutations directly contribute to pathogenesis in these models [30, 31] . This study represents the first systematic pathogenesis study of MARV strains in vivo and demonstrates the need for strain consideration when developing countermeasures against MARV.
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